Huayi Biotechnology
Huayi Biotechnology's purity-focus record is strongest in GHK-Cu and Tirzepatide, with repeated identity and high-purity clears despite fill swings and thin batch IDs. Retatrutide has recovered after earlier purity misses, while BPC-157 remains the soft spot on sparse evidence after a latest purity miss.
Huayi’s footprint splits between a closed Shoplazza storefront and an active Shop910-backed domain with cloaking and special-payment features. The report traces Tongkang-linked certificates, SV-branded vials, and review redirects while the true operator remains unresolved.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Huayi Biotechnology rows.
Cancel anytime
| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
| 16 Jun 2026 | Pass | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 15 Jun 2026 | Pass | Tirzepatide Huayi Biotechnology | lab name | View COA | |||
| 12 Jun 2026 | Pass | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 6 Jun 2026 | Pass | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 6 Jun 2026 | Incomplete | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 8 May 2026 | Pass | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 28 Apr 2026 | Pass | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 23 Apr 2026 | Pass | GHK-Cu Huayi Biotechnology | lab name | View COA | |||
| 29 Mar 2026 | Pass | Retatrutide Huayi Biotechnology | lab name | View COA | |||
| 18 Mar 2026 | Pass | Tirzepatide Huayi Biotechnology | lab name | View COA | |||
About Huayi Biotechnology test results from Finnrick
Huayi Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 4 peptides and 42 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Huayi Biotechnology peptides in this dataset are Tirzepatide (10 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 42 recent tests.